All Posts

Precision BioLogic Webinar 6-22-22: Dr. Geske

Thank to Elaine Benoit, Marketing and Communications Manager, Precision BioLogic for sharing the following: Join our webinar on June 22, 1 pm Eastern as we introduce F. Jon Geske, PhD, new Chief Scientific Officer for Precision BioLogic and Affinity Biologicals. With more than 30 years’ experience working in health and life sciences, Jon is a […]

EC Markers in COVID19 Thromboinflammation

The devastating COVID19 pandemic has led medical researchers led by Brandon M. Henry, MD, Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA to identify and characterize the pathophysiology of a number of thromboinflammation-related endothelial secretions. Some important terms relatively new to medical laboratory science include ADAMTS13/VWFag ratio, NETosis, and cell-free […]

Arterial Thrombosis

June, 2022 Cheat Sheet

Click here for our June 2022 Cheat Sheet, which will arrive in your mailbox soon.

May 2022 QQ: Thrombosis Risk Profile Summary

We had near-100% agreement on our May 2022 Quick Question, which attracted 45 voters: “What assay should be deleted from the thrombosis risk factor profile?” Here are our selections: Protein C 0% Protein S 2% [1] Antithrombin 2% [1] Activated protein C resistance 7% [3] Prothrombin G20210A mutation 4% [2] Methylenetetrahydrofolate reductase resistance [MTHFR] polymorphism […]

Quick Question Archive

Emicizumab in VWD

The opening plenary session of the World Federation of Hemophilia featured von Willebrand disease expert Dr. Peter Lenting, who reported on “Novel Treatment Options in von Willebrand Disease.” He reported on a case study in which emicizumab was used to successfully treat a type 3 VWD patient with anti-VWF inhibitors. The case study presentation appears […]

Bleeding Disorders

ISTH Guidelines for Treatment of TTP

Reminder, in 2020, the International Society for Thrombosis and Hemostasis [ISTH} released their “ISTH Diagnosis Guidelines” and “ISTH TTP Treatment Guidelines.”Click here for access to the guidelines and their supporting material.”

Bleeding Disorders

Chromogenic Factor IX Assay

On May 9, 2022, Precision BioLogic, Inc. [PBI] announced the release and international approval for their chromogenic factor IX assay. Click here for PBI’s press release. The product addresses the key need for accuracy when monitoring extended half-life coagulation factor concentrate therapy.

Bleeding Disorders

ASCLS Annual Meeting June 26–30

The ASCLS, AGT, and SAFMLS hybrid annual meeting [JAM] is planned for June 26–30, 2022 in Grand Rapids, MI. Click here for the details. George presents Operating Room Hemostasis Testing Wednesday, June 29, in-person 1:45–2:45 ET. The talk includes how the OR employs the activated clotting time or viscoelastometry to monitor heparin superdosing and reversal. […]

May 2022 Cheat Sheet

Click here for our May 2022 Cheat Sheet.

May 2022 QQ: Thrombosis Risk Profile

Our May 2022 Quick Question asks, “What assay should be deleted from the thrombosis risk factor profile?” Thrombosis risk testing has been available to us since von Kaulla first described “antithrombin 3” deficiency in 1972 using the “serum antithrombin” test. It gained momentum when Dahlbach described activated protein C resistance in 1994, and thrombosis risk […]

Quick Question Archive

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question